Zevra Therapeutics, Inc. (ZVRA): who owns it and who trades it
As of Nov 16, 2026, ZVRA insiders reported 13 open-market sales worth $2.5M and no purchases in the last 12 months, with 95% of the sale value made under pre-set 10b5-1 plans. The largest seller was Neil F. McFarlane (CEO), with $1.2M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Zevra Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ZVRA
157 funds and institutions reported ZVRA shares worth $670M at the end of Q2 2026, about 80% of the company. The largest holder is BlackRock, Inc. with 8.7%.
Funds and institutions (13F) 80%Everyone else 20%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 5.11M | 8.70% | $73.3M | +15% |
| FMR LLC (Fidelity) | 4.92M | 8.37% | $70.5M | +53% |
| Woodline Partners LP | 4.79M | 8.15% | $68.6M | +39% |
| Nantahala Capital Management, LLC | 3.59M | 6.12% | $51.6M | +43% |
| Vanguard Capital Management LLC | 2.64M | 4.49% | $37.8M | +7% |
| State Street Corp | 1.68M | 2.86% | $24.1M | +8% |
| Geode Capital Management, LLC | 1.54M | 2.62% | $22.1M | +12% |
| D. E. Shaw & Co., Inc. | 1.31M | 2.23% | $18.7M | +54% |
| Qube Research & Technologies Ltd | 1.24M | 2.11% | $17.8M | +47% |
| Morgan Stanley | 1.20M | 2.05% | $17.3M | +1% |
| Legal & General Group Plc | 1.20M | 2.05% | $17.2M | +3% |
| Dimensional Fund Advisors LP | 958,836 | 1.63% | $13.7M | +73% |
| Royce & Associates LP | 882,658 | 1.50% | $12.7M | -11% |
| 683 Capital Management, LLC | 855,000 | 1.46% | $12.3M | -12% |
| Kingdon Capital Management, L.l.c. | 775,000 | 1.32% | $11.1M | No change |
| Retirement Planning Co of New England, Inc. | 634,410 | 1.08% | $9.1M | -3% |
| Jupiter Topco LLC | 613,403 | 1.04% | $8.8M | – |
| Arrowstreet Capital, Limited Partnership | 597,162 | 1.02% | $8.6M | – |
| Goldman Sachs Group Inc | 545,551 | 0.93% | $7.8M | -27% |
| Vanguard Portfolio Management LLC | 541,109 | 0.92% | $7.8M | +16% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ZVRA insiders reported $0 of open-market purchases and $2.5M of sales. 95% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | Neil F. McFarlane | CEO | Sale plan | 20,000 | $11.25 | $225K | Form 4 |
| Aug 14, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sale plan | 42,666 | $11.13 | $475K | Form 4 |
| Aug 10, 2026 | Corey Michael Watton | Director | Sale | 12,300 | $11.25 | $138K | Form 4 |
| Jun 22, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sale plan | 34,557 | $12.68 | $438K | Form 4 |
| May 11, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sale plan | 1,794 | $11.30 | $20.3K | Form 4 |
| Feb 9, 2026 | Neil F. McFarlane | CEO | Sale plan | 14,625 | $8.56 | $125K | Form 4 |
| Feb 3, 2026 | Timothy J. Sangiovanni | Vice president | Sale plan | 3,000 | $9.18 | $27.5K | Form 4 |
| Feb 3, 2026 | Joshua Schafer | CCO | Sale plan | 10,500 | $9.19 | $96.5K | Form 4 |
| Feb 2, 2026 | Neil F. McFarlane | CEO | Sale plan | 91,000 | $9.38 | $854K | Form 4 |
| Jan 30, 2026 | Timothy J. Sangiovanni | Vice president | Sale plan | 1,750 | $8.82 | $15.4K | Form 4 |
| Jan 30, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sale plan | 4,080 | $8.83 | $36K | Form 4 |
| Jan 30, 2026 | Adrian W Quartel | Chief Medical Officer | Sale plan | 4,533 | $8.83 | $40K | Form 4 |
| Jan 30, 2026 | Joshua Schafer | CCO | Sale plan | 3,375 | $8.83 | $29.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Neil F. McFarlane | President and CEO, Director | – | $1.2M | Oct 12, 2026 |
| Rahsaan Thompson | Chief Legal & Compliance | – | $969K | Aug 14, 2026 |
| Corey Michael Watton | Director | – | $138K | Aug 10, 2026 |
| Joshua Schafer | CCO | – | $126K | Feb 3, 2026 |
| Timothy J. Sangiovanni | SVP, Finance & Corp Controller | – | $43K | Feb 3, 2026 |
| Adrian W Quartel | Chief Medical Officer | – | $40K | Jan 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ZVRA short interest
High short interest. 11.0% of ZVRA shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 48%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.56M ZVRA shares were sold short, 11.0% of the shares outstanding, up 5.3% from the report before. At the average daily volume of 690,195 shares, buying them all back would take about 9.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.56M | 11.02% | +5% | 690,195 | 9.5 |
| Oct 15, 2026 | 6.23M | 10.48% | -13% | 879,203 | 7.1 |
| Sep 30, 2026 | 7.15M | 12.04% | +25% | 998,161 | 7.2 |
| Sep 15, 2026 | 5.74M | 9.66% | -1% | 905,980 | 6.3 |
| Aug 31, 2026 | 5.77M | 9.72% | -11% | 773,319 | 7.5 |
| Aug 14, 2026 | 6.47M | 10.90% | -9% | 1.12M | 5.8 |
| Jul 31, 2026 | 7.13M | 12.01% | -9% | 1.62M | 4.4 |
| Jul 15, 2026 | 7.80M | 13.28% | +20% | 1.43M | 5.4 |
| Jun 30, 2026 | 6.49M | 11.05% | -0% | 1.50M | 4.3 |
| Jun 15, 2026 | 6.52M | 11.11% | +9% | 2.33M | 2.8 |
| May 29, 2026 | 5.96M | 10.16% | +34% | 2.18M | 2.7 |
| May 15, 2026 | 4.44M | 7.57% | -11% | 1.76M | 2.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Zevra Therapeutics company events
Zevra Therapeutics filed 9 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 16, 2026AgreementZevra Therapeutics, Inc. entered into an Asset Purchase and Settlement Agreement with Commave Therapeutics SA to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned Commave Therapeutics SA v. Filing
- Mar 9, 2026LeadershipThe Company appointed Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and as principal financial officer, effective March 10, 2026. Filing
- Dec 17, 2025LeadershipThe board of directors of Zevra Therapeutics, Inc. appointed Timothy Sangiovanni, the Company’s current Senior Vice President, Finance and Corporate Controller and principal accounting officer, as interim principal financial officer, effective as of January 1, 2026. Filing
- Dec 2, 2025LeadershipWendy Dixon notified the board of directors of Zevra Therapeutics, Inc. that she was resigning from the Board and each committee of the Board on which she served, subject to the Board’s acceptance. Filing
- Nov 20, 2025LeadershipR. LaDuane Clifton, the Chief Financial Officer and Treasurer and principal financial officer of Zevra Therapeutics, Inc. notified the Company of his decision to resign from his position, effective December 31, 2025, in order to pursue other professional opportunities. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Zevra Therapeutics financials
Famous investors that hold ZVRA
2 of the 50 well-known investors we track reported holding ZVRA in their latest 13F filing. The largest position is Ken Griffin's, worth $4.9M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 448,934 | $4.9M | 0.0% | +3590% |
| Israel Englander · Millennium Management | Q3 2026 | 408,339 | $4.5M | 0.0% | +351% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ZVRA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 9.4% |
| Nov 5, 2026 | FMR LLC | 13G/A | 9.4% |
Questions about Zevra Therapeutics, Inc. (ZVRA) stock
Who owns the most ZVRA stock?
The largest reported owner of Zevra Therapeutics, Inc. (ZVRA) is BlackRock, Inc., with 8.7% of the company. In total, 157 funds and institutions reported holding ZVRA at the end of Q2 2026, together about 80% of the shares. See the largest owners.
Are ZVRA insiders buying or selling?
In the last 12 months, ZVRA insiders reported no open-market purchases and 13 sales worth $2.5M. The latest trade was on Oct 12, 2026. See every trade.
What is the short interest in ZVRA?
As of Oct 30, 2026, 6.56M ZVRA shares were sold short, 11.0% of the shares outstanding, up 5.3% from the report before. At the average daily volume of 690,195 shares, buying them all back would take about 9.5 trading days (days to cover). See the history.
Which famous investors hold ZVRA?
2 of the 50 well-known investors we track reported ZVRA in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $4.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.